Oct 10, 2023

  • Pharmaceuticals
  • R&D

Roche Announces Updates on Retinal Vein Occlusion (RVO) for Vabysmo

TOKYO, October 10, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche issued a press release regarding long-term results of its two phase III clinical trials (BALATON study and COMINO study) for Vabysmo® (faricimab) for retinal vein occlusion (RVO).

Please refer to the link below for details of the press release:

Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies




  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Hideki Sato
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top